Key Highlights
- C the Signs secures $8M from Khosla Ventures to expand from the U.K. to the U.S.
- AI-powered platform has helped detect tens of thousands of cancers within the NHS.
- Identifies 20.7% of breast cancers up to five years earlier than standard methods.
- AI model achieved 93.8% sensitivity for colorectal cancer, comparable to a colonoscopy.
- Aims to shift cancer risk identification to primary care, improving early-stage survival rates.
Source: Business Wire
Notable Quotes
“We started C the Signs to move the burden of identifying cancer risk away from the emergency room, when it’s often too late. Instead, we want to enable primary care physicians to identify cancer risk at the earliest possible stage, to substantially increase the chance of survival.” — Dr. Bea Bakshi, MD, Co-Founder & CEO at C the Signs
“Early cancer detection is the best way to beat the disease, and AI is primed to catch warning signs long before symptoms appear.” — Hal Paz, Operating Partner at Khosla Ventures
Why This Matters
Early cancer detection dramatically improves survival rates, yet many cancers are diagnosed too late. C the Signs’ AI-driven approach enhances physicians’ ability to detect cancer risk based on a wide range of patient data, beyond traditional screening methods. With this $8M investment, the company can scale its impact in the U.S., potentially transforming cancer diagnosis and treatment, reducing disparities, and saving lives.
